Broncus Holding Corp. (2216) AI Stock Analysis

• Market Cap: HK$724.37M
• Dividend Yield: N/A
• Average Volume (3M): 2.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: -30.60%
• EPS Growth: 28.61%
• Country: HK
• Employees: 200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 528,737,060
• 10 Day Avg. Volume: 1,907,700
• 30 Day Avg. Volume: 2,030,864
• PEG Ratio: 0.05
• Price to Book (P/B): 0.22
• Price to Sales (P/S): 4.56
• P/FCF Ratio: -3.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): HK$16.96M

• Rating: 41 Neutral
• Price Target: HK$2.00 ▼(-15.25% Downside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is held down primarily by weak financial performance (persistent losses, declining revenue, and poor cash generation). Technical indicators also point to a continuing downtrend despite oversold readings. Valuation provides limited support because a negative P/E reflects ongoing losses and no dividend data is available.

Positive Factors

High Gross Margin

A ~75.5% gross margin indicates strong unit economics and pricing power for its bronchoscopic devices. Durable product-level margins can sustain R&D and regulatory costs, buffer operating losses, and improve the company's ability to scale profitably if revenue stabilizes over months.

Conservative Balance Sheet

A 96.36% equity ratio and minimal leverage provide financial flexibility and low interest burden. This conservatism reduces immediate solvency risk and can allow the firm to fund operations or pursue strategic initiatives during downturns, though declining assets remain a watch item.

Recurring Consumables and Services

Recurring revenue from consumables and service contracts creates a more predictable revenue base and higher lifetime customer value than one-time device sales. This structural revenue mix supports margin stability and steadier adoption in hospitals over the medium term.

Negative Factors

Sustained Revenue Declines

A ~30.6% revenue decline over the recent period signals persistent loss of sales momentum. Continued top-line contraction undermines scale, weakens fixed-cost absorption, reduces pricing leverage, and limits resources available for product development and commercial expansion over the next several months.

Large Persistent Losses

A net margin of -188.23% reflects deep and persistent unprofitability, indicating the core business is not generating positive bottom-line returns. Such large losses can deplete equity, force dilutive capital raises, and constrain investment in clinical evidence and commercialization needed for long-term recovery.

Weak Cash Generation

Zero operating cash flow in 2024 and historically negative free cash flow show poor cash conversion despite high gross margins. Weak cash generation increases reliance on external financing, limits spending on R&D and sales, and raises liquidity risk if operating losses continue.

Broncus Holding Corp. Business Overview & Revenue Model

Company Description

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

How the Company Makes Money

Broncus Holding Corp. generates revenue primarily through the sale of its medical devices and related products to hospitals, clinics, and healthcare providers. Key revenue streams include direct sales of its bronchoscopic devices and consumables, as well as recurring revenue from service agreements and product maintenance. The company may also engage in partnerships with other medical technology firms and research institutions to enhance its product offerings and expand its market reach. Additionally, Broncus may benefit from reimbursement programs and funding from healthcare systems, which facilitate the adoption of its technologies in clinical settings.

Broncus Holding Corp. Financial Statement Overview

Summary

Financial performance is weak overall: sustained revenue declines and very large losses (2024 net margin -188.23%) outweigh the strong gross margin (~75.5%) and low leverage. Cash flow is a key concern, with operating cash flow at zero in 2024 and historically negative free cash flow.

Income Statement

Broncus Holding Corp. displays a challenging income statement profile with consistent revenue declines from 2021 to 2024, despite experiencing a peak in 2020. The gross profit margin remains high at around 75.5% in 2024, reflecting efficient cost management relative to revenue. However, significant net losses and negative EBIT and EBITDA margins, particularly in 2024 with a net profit margin of -188.23%, indicate persistent profitability issues.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio of 96.36% in 2024, suggesting good asset coverage by equity. The debt-to-equity ratio is low at 0.0019, indicating minimal leverage. However, the company has experienced declines in total assets and stockholder equity over time, posing potential risks if trends continue.

Cash Flow

Broncus Holding Corp. faces significant cash flow challenges. The operating cash flow to net income ratio indicates a disconnect between earnings and cash flow generation, as evidenced by zero operating cash flow in 2024. The lack of free cash flow growth and historically negative free cash flow further stress the company's liquidity position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.08M	8.13M	10.26M	9.41M	10.89M	3.26M
Gross Profit	4.40M	6.14M	7.23M	7.32M	8.74M	2.51M
EBITDA	-20.69M	-18.96M	-25.06M	-30.58M	-233.31M	-45.95M
Net Income	-15.15M	-15.30M	-28.09M	-28.04M	-236.18M	-48.24M
Balance Sheet
Total Assets	165.67M	175.90M	195.81M	221.94M	252.81M	39.88M
Cash, Cash Equivalents and Short-Term Investments	130.52M	139.11M	156.88M	187.91M	227.21M	18.79M
Total Debt	47.00K	318.00K	2.35M	1.47M	1.95M	6.12M
Total Liabilities	5.29M	6.42M	10.44M	8.48M	10.39M	162.32M
Stockholders Equity	160.38M	169.48M	185.37M	213.46M	242.42M	-120.51M
Cash Flow
Free Cash Flow	-5.99M	-10.32M	-26.84M	-31.81M	-33.38M	-16.76M
Operating Cash Flow	-5.91M	-10.00M	-26.13M	-30.95M	-31.49M	-15.59M
Investing Cash Flow	-21.16M	-25.91M	5.49M	-87.57M	-1.75M	-1.09M
Financing Cash Flow	-3.21M	-1.02M	-1.46M	-572.00K	241.82M	32.23M

Broncus Holding Corp. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.36
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2216, the sentiment is Negative. The current price of 2.36 is above the 20-day moving average (MA) of 1.63, above the 50-day MA of 2.02, and below the 200-day MA of 2.49, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 19.77 is Positive, neither overbought nor oversold. The STOCH value of 13.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2216.

Broncus Holding Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6609	61 Neutral	HK$1.62B	13.30	3.84%	―	32.93%	―
2500	53 Neutral	HK$1.01B	-1.91	-26.80%	―	-8.56%	-14.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
2170	44 Neutral	HK$506.02M	-2.91	-20.60%	―	11.43%	4.88%
2235	44 Neutral	HK$3.14B	-495.98	-1.35%	―	49.86%	80.35%
2160	43 Neutral	HK$4.41B	-218.71	0.22%	―	-4.38%	―
2216	41 Neutral	HK$724.37M	-4.03	-8.93%	―	-30.60%	28.61%

Broncus Holding Corp. Corporate Events

Broncus’ COPD Device Accepted for China’s Innovative Medical Device Fast-Track Review

Broncus Holding Corporation announced that its BroncTarget® Targeted Lung Denervation Radiofrequency Ablation System has been accepted into China’s National Medical Products Administration Innovative Medical Device Special Review Procedure, signaling regulatory recognition of the product’s technological originality and potential clinical value in treating moderate to severe COPD. The system uses a bronchoscopy-based, radiofrequency-driven approach to targeted lung denervation, combining multi-electrode design, adjustable loop diameter, differentiated energy output, and real-time monitoring to enhance efficacy and safety, and its confirmatory clinical trial is currently underway with patient recruitment progressing across 28 hospitals nationwide, underscoring the company’s push to expand its therapeutic portfolio in advanced COPD management, albeit with no guarantee of eventual commercialization.

The most recent analyst rating on (HK:2216) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.

Broncus Holding to Buy US$15 Million Stake in Structural Heart Intervention Player

Broncus Holding Corporation has agreed, through a wholly owned subsidiary, to acquire 157,800 Series B preferred shares in an unnamed target company for US$15 million, representing 1.05% of the target’s fully diluted share capital. The cash transaction, structured with 90% payable at closing and 10% following proof of tax payments by the seller, reflects Broncus’s confidence in the target’s business prospects and the growth potential of interventional treatments for mitral and tricuspid valves, and it qualifies as a discloseable transaction under Hong Kong listing rules, signaling a measured but strategic expansion of its stake in the structural heart intervention market. The deal remains subject to closing conditions, including the accuracy of purchaser representations and fulfillment of contractual obligations, so completion is not yet assured, and investors are cautioned about related trading risks.

The most recent analyst rating on (HK:2216) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.

Broncus Holding Corp. Updates on Share Issue and Strategic Fund Allocation

Broncus Holding Corp. has announced an update on its proposed issue of shares under a general mandate, with the completion of necessary regulatory approvals in progress. The company plans to utilize the net proceeds of approximately HK$326.5 million to fund research and development, commercialization efforts, and global expansion, including establishing an overseas headquarters in Ireland. This strategic allocation aims to enhance Broncus’s market positioning and operational capabilities in the medical devices sector.

The most recent analyst rating on (HK:2216) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.